Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 4
2004 12
2005 4
2006 7
2007 4
2008 9
2009 12
2010 15
2011 10
2012 17
2013 15
2014 16
2015 25
2016 26
2017 27
2018 28
2019 34
2020 41
2021 30
2022 46
2023 31
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

371 results

Results by year

Filters applied: . Clear all
Page 1
This Issue 30-5.
Shinohara N. Shinohara N. Int J Urol. 2023 May;30(5):421. doi: 10.1111/iju.15186. Int J Urol. 2023. PMID: 37199071 No abstract available.
New year's greetings.
Shinohara N. Shinohara N. Int J Urol. 2021 Jan;28(1):5. doi: 10.1111/iju.14479. Int J Urol. 2021. PMID: 33429463 No abstract available.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
New year's greetings.
Shinohara N. Shinohara N. Int J Urol. 2020 Jan;27(1):5. doi: 10.1111/iju.14180. Int J Urol. 2020. PMID: 31925861 No abstract available.
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Yamada S, et al. Among authors: shinohara n. Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 10.1007/s00262-023-03388-5. Epub 2023 Feb 16. Cancer Immunol Immunother. 2023. PMID: 36795123
Surgical strategy for orthotopic kidney transplantation.
Hotta K, Miura M, Tanaka T, Tanabe T, Masumori N, Shinohara N. Hotta K, et al. Among authors: shinohara n. Int J Urol. 2024 Jan 31. doi: 10.1111/iju.15418. Online ahead of print. Int J Urol. 2024. PMID: 38297483 No abstract available.
Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease.
Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Abe-Takahashi Y, Kusakabe N, Shinohara N. Kitta T, et al. Among authors: shinohara n. Int J Mol Sci. 2020 Sep 7;21(18):6520. doi: 10.3390/ijms21186520. Int J Mol Sci. 2020. PMID: 32906613 Free PMC article. Review.
Particle therapy for prostate cancer: The past, present and future.
Ishikawa H, Tsuji H, Murayama S, Sugimoto M, Shinohara N, Maruyama S, Murakami M, Shirato H, Sakurai H. Ishikawa H, et al. Among authors: shinohara n. Int J Urol. 2019 Oct;26(10):971-979. doi: 10.1111/iju.14041. Epub 2019 Jul 8. Int J Urol. 2019. PMID: 31284326 Free PMC article. Review.
371 results